Evidence for Mycoplasma ssp., Chlamydia pneunomiae, and Human Herpes Virus-6 Coinfections in the Blood of Patients With Autistic Spectrum Disorders Garth L. Nicolson,1* Robert Gan,1 Nancy L. Nicolson,1 and Joerg Haier1,2 1The Institute for Molecular Medicine, Huntington Beach, California 2Department of Surgery, University Hospital, Munster, Germany We examined the blood of 48 patients from central and southern California diagnosed with autistic spectrum disorders (ASD) by using forensic polymerase chain reaction and found that a large subset (28/48 or 58.3%) of patients showed evidence of Mycoplasma spp. infections compared with two of 45 (4.7%) age-matched control subjects (odds ratio = 13.8, P < 0.001). Because ASD patients have a high prevalence of one or more Mycoplasma spp. and sometimes show evidence of infections with Chlamydia pneumoniae, we examined ASD patients for other infections. Also, the presence of one or more systemic infections may predispose ASD patients to other infections, so we examined the preva lence of C. pneumoniae (4/48 or 8.3% positive, odds ratio = 5.6, P < 0.01) and human herpes virus-6 (HHV- 6, 14/48 or 29.2%, odds ratio = 4.5, P < 0.01) coinfections in ASD patients. We found that Mycoplasma-positive and -negative ASD patients had similar percentages of C. pneumoniae and HHV-6 infections, suggesting that such infections occur independently in ASD patients. Control subjects also had low rates of C. pneumoniae (1/48 or 2.1%) and HHV-6 (4/48 or 8.3%) infections, and there were no coinfections in control subjects. The results indicate that a large sub- set of ASD patients shows evidence of bacterial and/or viral infections (odds ratio 1⁄4 16.5, P < 0.001). The significance of these infections in ASD is discussed in terms of appropriate treatment. Autism was first identified in 1943 (Kanner, 1943), and autism patients generally suffer from an inability to communicate properly, form relationships with others, and respond appropriately to their environments. Autism patients often display repetitive actions and develop troublesome fixations with specific objects, and they are often sensitive to certain sounds, tastes, and smells. Autism patients do not all share the same signs and symp- toms but tend to share certain social, communication, motor, and sensory problems that affect their behavior in predictable ways (Berney, 2000). Autism and related dis- orders have been recently placed into a multidisorder category called autistic spectrum disorders (ASD), which includes autism, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), and other disorders (Keen and Ward, 2004). The criteria for diagnosis of ASD are, in general terms, the presence of a triad of impairments in social interaction, communication, and imagination (Wing et al., 2002). These signs and symptoms are thought to be due to abnormalities in brain function or structure and are thought to have a genetic basis (Folstein and Rosen-Sheidley, 2001; Veenstra-Vanderweele et al., 2003). The incidence of ASD is currently estimated at 1 in 1,000 children, and in genetically predisposed families the disorder is *100 times higher in incidence than in the general population (Folstein and Rosen-Sheidley, 2002). The concordance rate in monozygotic twins is 70–90%, whereas in dizygotic twins the rate is close to 0%, suggesting a strong genetic component (Veenstra- Vanderweele et al., 2003). In some patients, there are also a number of other less specific chronic signs and symptoms. Among these are fatigue, headaches, gastrointestinal and vision prob- lems, and occasional intermittent low-grade fevers and other signs and symptoms that are generally excluded in the diagnosis of ASD. These suggest that a subset of ASD patients may suffer from bacterial or viral infections (Takahashi et al., 2001). There are several reasons for this, including the nonrandom or clustered appearance of ASD, sometimes in immediate family members or par- ticular regions, the presence of certain signs and symptoms associated with infection, the cyclic course of the illness, and in some cases its response to antimicrobial therapies. Although no single underlying cause has been established for ASD, there is growing awareness that ASD can have an infectious nature that may be a cofactor for the illness or appear as an opportunistic infection(s) that can aggravate patient morbidity (Takahashi et al., 2001; Yamashita et al., 2003; Libbey et al., 2005). Identifying systemic infections, such as those produced by Myco- plasma species (Huang et al., 1998; Nijs et al., 2002; Nicolson et al., 2003a,b, 2005a), Chlamydia pneumoniae (Chia and Chia, 1999; Nicolson et al., 2003a,b), and human herpes virus-6 (HHV-6; Braun et al., 1997; Campadelli-Fiume et al., 1999; Nicolson et al., 2003a,b), is likely to be important in determining the treatment strategies for many ASD patients. These infections can penetrate the CNS and are associated with other neurological diseases (Nicolson et al., 2002). In addition, heavy metal, chemical, and environmental exposures also appear to be important in ASD (Eppright et al., 1996; Colborn, 2004; Davidson et al., 2004). Here we examined ASD patients to determine whether a subset of patients shows evidence of infection with Mycoplasma spp., C. pneumoniae, or HHV-6. Because these infections can cause neurological signs and symptoms (Baseman and Tully, 1997; Nasralla et al., 1999, 2000; Nicolson et al., 2003a), they may be important in ASD. Previously we found that children of Mycoplasma- positive Gulf War veterans were over 18 times more likely to come down with Mycoplasma fermentans than the general population (Nicolson et al., 2003c), and ASD diagnoses were found in their children. In addition, examination of a group of autism patients from civilian families revealed that there was a high incidence of mycoplasmal infections, including M. fermentans, M. pneumo- niae, and M. hominis (Nicolson et al., 2005b). Because mycoplasmal infections can often be found as coinfections with C. pneumoniae or HHV-6 (Nicolson et al., 2003a,b, 2005a), we examined ASD patients to see whether they had evidence of coinfections of Mycoplasma spp., C. pneumoniae, and HHV-6. MATERIALS AND METHODS Patients All ASD patients (N 1⁄4 48) were randomly recruited from families in contact with patient support groups and were referred from central and southern California physicians after diagnosis with ASD according to the International classification of diseases (ICD-10) and the Diagnostic and statistical manual of mental disorders (DSM-IV). All patients were assessed via the Autism Diagnostic Interview-Revised (ADI-R; Lord et al., 1997) and Childhood Autism Rating Scale (CARS; Van Bourgondien et al., 1992; Pilowsky et al., 1998). All of the patients in the study were ASD patients; most (45/48) had a diagnosis of autism, and six of 48 were diagnosed with ADD (three of which were also diagnosed with autism) and nine autism patients with Asperger’s syndrome. Patients also underwent a medical history, a sign/symptom illness survey was taken, and they had routine laboratory tests. Additionally, all parents were questioned about medication use during the 3 months prior to the study, and patients had to be free of antibiotic treatment for 2 months prior to blood collection. Control subjects were from families randomly recruited for unrelated studies (N 1⁄4 45); they had to be free of any disease or behavioral disorder, and they had not undergone antibiotic treatment for 3 months prior to blood collection. Blood Collection Blood was collected in EDTA-containing tubes and im- mediately brought to ice-bath temperature as described previously (Nijs et al., 2002; Nicolson et al., 2003a–c, 2005a). Samples were shipped with wet ice by overnight air courier to the Institute for Molecular Medicine for analysis. All blood samples were blinded. Whole blood (50 ll) was used for prep- aration of DNA using Chelex (Bio-Rad, Hercules, CA), as follows. Blood cells were lysed with nano-pure water (1.3 ml) at room temperature for 30 min. After centrifugation at 13,000g for 2 min, the supernatants were discarded. Chelex solution (200 ll) was added, and the samples were incubated at 568C and at 1008C for 15 min each. Aliquots from the centrifuged samples were used immediately for polymerase chain reaction (PCR) or flash frozen and stored at –708C until use. Multiple aliquots were used for experiments on all patient samples. Detection of Mycoplasma by Forensic PCR Amplification of the target gene sequences (Nicolson et al., 2003a,b, 2005a) was performed in a total volume of 50 ll PCR buffer (10 mM Tris-HCl, 50 mM KCl, pH 9) containing 0.1% Triton X-100; 200 lm each of dATP, dTTP, dGTP, and dCTP; 100 pmol of each primer; and 0.5– 1 lg of chromosomal DNA. Purified mycoplasmal DNA (0.5–1 ng of DNA) was used as a positive control for amplification. The efficiency of the PCR process was monitored by amplification of b-actin mRNA. Additional primer sets were used to confirm the species specificity of the reaction (Nic- AQ1 olson et al., 2003a–c, 2005a). The amplification was carried out for 40 cycles with denaturing at 948C and annealing at 608C (genus-specific primers and M. penetrans) or 558C (M. pneumoniae, M. hominis, M. fermentans). Extension temperature was 728C in all cases. Finally, product extension was performed at 728C for 10 min. Negative and positive controls were present in each experiment. The amplified samples were run on a 1% agarose gel containing ethidium bromide in TAE buffer (0.04 M Tris-acetate, 0.001 M EDTA, pH 8.0). After denaturing and neutralization, Southern blotting was performed. The DNA was amplified for 30 cycles using standard cycle parameters and the product evaluated by agarose gel electrophoresis. The efficiency of the PCR process was monitored by amplification of b-actin mRNA. The presence of amplification inhibitors was evaluated by spiking negative samples. C. pneumoniae-specific sequence of the PCR product was confirmed by Southern blot and dot-blot hybridization with a 21-mer internal probe: 50 -CGTTGAGTCAACGACTTAAGG-30 30 -end-labelled with digoxigenin-UTP or 32P-labeled probe. HHV-6 Detection by Forensic PCR PCR detection of HHV-6A was performed as described above, except that the conditions and primers differ, and plasma was used for polynucleotide isolation to detect active infections or cell-released virus (Nicolson et al., 2003a,b). PCRs were carried out using the following HHV-6A-specific primers: 50-GCGTTTTCAGTGTGTAGTTCGGCAG-30 (up- stream) and 50-TGGCCGCATTTCGTACAGATACGGA- GG-30 (downstream). The nucleotides were amplified for 30 cycles with standard cycle parameters, and the product was evaluated by agarose gel electrophoresis. The efficiency of the PCR process was monitored by amplification of b-actin mRNA. The presence of amplification inhibitors was evaluated by spiking negative samples. HHV-6A-specific oligonucleotides in the PCR product were identified by Southern blot and dot-blot hybridization using a 21-mer internal probe: 50- Type Culture Collection (Manasses, VA). The primers produced the expected amplification product size in all test species, which was confirmed by hybridization using the appropriate 32P-labeled internal probe (Nasralla et al., 1999). Amounts as low as a few femtograms of purified DNA were detectable for all species with the specific internal probes. There was no cross-reactivity between the internal probes of one species and the PCR product from another species (Nasralla et al., 2000; Nicolson et al., 2003a–c). The techni- ques used have been validated in various studies (see, e.g., Berg et al., 1996; Bernet et al., 1995). Statistical Analysis Subjects’ demographic characteristics were assessed via descriptive statistics and Student’s t-tests (independent-samples test, t-test for equality of means, two-tailed). The 95% confidence interval was chosen for minimal significance. Odds ratios were calculated by using logistic regression (logit method) in Statistica 5.5 (Statsoft, Tulsa, OK). In some cases, Pearson v2 test was performed to compare prevalence data between patients and control subjects. RESULTS Patients and Control Subjects ASD patients and control subjects were approxi- mately similar in age (control subjects mean age 1⁄4 8.4; ASD patients mean age 1⁄4 7.9). ASD patients differed significantly according to sex distribution (P < 0.05); 75% of the patients were male, whereas 25% of the patients were female. Similarly, 62.2% of control subjects were male, whereas 37.8% were female. Patients were from central and southern California and resided in approximately equally in rural and urban environments (Table I). T1 Bacterial and Viral Infections in ASD Patients By using PCR, we examined ASD patients’ blood for the presence of bacterial and viral infections. Evi- dence for Mycoplasma spp. infections was found in 28 of 48 or 58.3% of ASD patients and two of 45 or 4.7% age-matched control subjects (odds ratio 1⁄4 13.8, P < 0.001). C. pneumoniae infections were found in four of 48 or 8.3% of ASD patients and in one of 45 or 2.1% of control subjects (odds ratio 1⁄4 5.6, P < 0.01). We also examined the incidence of HHV-6 infections in ASD patients and found that 14 of 48 or 29.2% of ASD patients were positive compared with four of 45 or 8.8% age-matched control subjects (odds ratio 1⁄4 4.5, P < 0.01). We did not find any multiple coinfections in control subjects . The rate of positive results in control subjects was similar to that in previous studies (Nasralla et al., 2000; Nicolson et al., 2003a–c, 2005). The differences between infections in ASD patients and control subjects were highly significant (odds ratio 1⁄4 16.5, P < 0.001). Significant differences were not found in the prevalence of infections between urban and rural patients, between male and female patients, or between autism and other ASD diagnoses. Multiple Coinfections in ASD Patients We studied multiple infections in patients by examining whether patients who were positive (or nega- tive) for one type of infection also tested positive for other infections. Eight of fourteen patients with HHV-6 positive results (57.1%) were also positive for mycoplas- mal infections. C. pneumoniae infections were observed in two of four mycoplasma-positive ASD patients and two of four mycoplasma-negative patients. Therefore, we did not find a preference for particular multiple infections in patient subsets. Multiple mycoplasmal infections were found in 12 of 48 or 25% of ASD patients; only M. fermentans plus other species were found. We exam ined 45 control subjects who did not show clinical signs and symptoms and found that only two were positive for a single mycoplasma species (Mycoplasma pneumoniae. Differences between ASD patients and control subjects were highly significant. DISCUSSION Previously we found that chronic infections in Gulf War veterans diagnosed with Gulf War illness could also be found in symptomatic family members, including their children (Nicolson et al., 2003c). In the families chosen for this study, chronic illnesses were not reported until after the veteran in the family returned from the Gulf War. Interestingly, though not reported, common diagnoses of illness in the children of Gulf War veterans with mycoplasmal infections included ASD-like illnesses, among others, and we found the same infection, primar ily M. fermentans, in both the sick adults and the children in these families. The data suggested that the M. fermentans was likely passed from the veterans to their children (Nicolson et al., 2003c). Although preliminary and not carefully analyzed or studied further, this result suggested that infections might be present in ASD patients. Therefore, we examined a small group of patients (28 patients with autism-like disorders, age range 3–12 years) in cen- tral California for evidence of mycoplasmal infections, and we found that slightly over one-half were positive for one of four species of Mycoplasma (Nicolson et al., 2005b). In contrast to the children in military families among whom primarily one species of Mycoplasma was found (usually M. fermentans), most ASD patients in central California were found to have single or multiple mycoplasmal infections involving M. pneumoniae, M. fermentans, M. hominis, or M. genitalium. We found simi- lar results in the present study, but, in addition to infec- tions with Mycoplasma spp., we also examined two other commonly found infections in chronically ill patients, C. pneumoniae and HHV-6 (Nicolson et al., 2003a,b). The results suggested that infections are a common feature in ASD. Consistent with this hypothesis is the finding that autism occurs at greater prevalence during periods of more frequent hospitalizations for bronchitis or pneumonia (Tanoue et al., 1988), and maternal viral infections during the second trimester of pregnancy are associated with increased risk of autism in the offspring (Ciaranello and Ciaranello, 1995; Wilkerson et al., 2002). Infections are thought to play important roles in a variety of neurodevelopmental diseases, including ASD (Horning et al., 1999; Nicolson et al., 2002; Libbey et al., 2005). Such infections could be involved in the etiology of the disease, or more likely they could cause comorbid states (Nicolson et al., 2003a,b, 2005). We found a higher prevalence of Mycoplasma spp. (odds ratio 1⁄4 13.8), C. pneumoniae (odds ratio 1⁄4 5.6), and HHV-6 (odds ratio 1⁄4 4.5) among children diagnosed with ASD compared with age-matched control subjects. The PCR techniques used in the present study have been validated in other studies (Nicolson et al., 2003a–c, 2005). There are some similarities between the environmental exposures of Gulf War veterans and children with ASD. Both groups were given multiple vaccines prior to their illnesses, and heavy metals and chemicals have been found in both groups (Eppright et al., 1996; Boyd, 2004; Buttram, 2004; Davidson et al., 2004; Geier and Geier, 2004), but these findings are not universal (Jackson and Garrod, 1978). There are reports of clinical improvement with treatment for these environmental exposures (for review see Kidd, 2002). There were limitations in the present preliminary study, including sample size. Although all of the patients in the study were ASD patients, most (39/48) had a diagnosis of autism, and six of 48 were diagnosed with Asperger’s syndrome, wherease six of 48 were diagnosed with ADD (three of whom were also diagnosed with autism). Removal of the two sets of six patients from the analysis or analysis of the data by sex did not change the results or conclusions. Other factors, such as geogra- phy, family socioeconomic status, vaccination records, and family educational levels were not analyzed. There were also limitations in the diagnostic tests performed on patients. Future studies should include additional tests on the patients’ intellectual capacities with regard to abstract- ing and generalization as well as verbal and nonverbal communications. The infections found in ASD patients in the present and previous studies (Takahashi et al., 2001; AQ2 Yamashita et al., 2003; Libbey et al., 2003; Nicolson et al., 2003c, 2005) could have originated from vaccines or from opportunistic infections in immune-suppressed children. Bacterial contamination has been found in commercial vaccines, and in one study 6% of commercial vaccines were contaminated with mycoplasmas (Thornton, 1986). Thus the appearance of infections in children diagnosed with ASD may eventually be linked to the multiple vaccines received during childhood either as a source or from opportunistic infections in immune;suppressed recipients of multiple vaccines. Although the etiology of ASD is currently unknown and is thought to involve both genetic and environmental factors (Lipkin and Hornig, 2003; Libbey et al., 2005), the infections found in ASD patients should be considered along with other factors in the management of these disorders (Kidd, 2002). REFERENCES Baseman J, Tully J. 1997. Mycoplasmas: sophisticated, reemerging, and burdened by their notoriety. Emerg Infect Dis 3:21–32. Berg S, Lueneberg E, Frosch M. 1996. Development of an amplification and hybridization assay for the specific and sensitive detection of Mycoplasma fermentans DNA. Mol Cell Probes 10:7–14. Bernet C, Garret M, de Barbeyrac B, Bebear C, Bonnet J. 1995. Detec- tion of Mycoplasma pneumoniae by using the polymerase chain reac- tion. J Clin Microbiol 27:2492–2496. Berney TB. 2000. Autism—an evolving concept. Br J Psychiatry 176: 20–25. Braun DK, Dominguez G, Pellett PE. 1997. Human herpesvirus-6. Clin Microbiol Rev 10:521–567. Buttram HE. 2004. Vaccine scene 2004 update: still MMR vaccination, mercury and aluminum. Med Veritas 1:130–135. Campadelli-Fiume G, Mirandela P, Menetti L. 1999. Human herpesvi- rus-6: an emerging pathogen. Emerg Infect Dis 5:353–366. Chia JKS, Chia LY. 1999. Chronic Chlamydia pneumoniae infection: a treatable cause of chronic fatigue syndrome. Clin Infect Dis 29:452–453. Ciaranello AL, Ciaranello RD. 1995. The neurobiology of infantile autism. Annu Rev Neurosci 18:101–128. Colborn T. 2004. Neurodevelopment and endocrine disruption. Environ Health Perspect 112:944–949. Davidson PW, Myers GJ, Weiss B. 2004. Mercury exposure and child development outcomes. Pediatrics 113:1023–1029. Eppright TD, Sanfacon JA, Horwitz EA. 1996. Attention deficit hyperac- tivity disorder, infantile autism and elevated blood-lead: a possible relationship. Mol Med 93:136–138. Folstein SE, Rosen-Sheidley B. 2001. Genetics of autism: complex aeti- ology for a heterogeneous disorder. Nat Rev Genet 2:943–955. Geier DA, Geier MR. 2004. A comparative evaluation of the effects of MMR immunization and mercury doses from thimerosal-containing childhood vaccines on the population prevalence of autism. Med Sci Monit 10:133–139. Haley B. 2005. Hypothesis. Thimerosal in mandated vaccinations is the major etiological agent in the recent increase in autism and attention deficit/hyperactive disorder. Med Veritas 2:438–440. Horning M, Weissenbock H, Horscroft N, Lipkin WI. 1999. An infection-based model of neurodevelopmental damage. Proc Natl Acad Sci USA 96:12102–12107. Huang W, See D, Tiles J. 1998. The prevalence of Mycoplasma incognitus in the peripheral blood mononuclear cells of normal controls or patients with AIDS or chronic fatigue syndrome. J Clin Microbiol 231:457–467. Jackson MJ, Garrod PJ. 1978. Plasma zinc, copper and amino acid levels in the blood of autistic children. J Autism Child Schizophr 8:203–208. Kanner L. 1943. Autistic disturbances of affective contact. Nerv Child 2:217–250. Keen D, Ward S. 2004. Autistic spectrum disorder. Autism 8:39–58. Kidd P. 2002. Autism, and extreme challenge to integrative medicine. Part II: medical management. Altern Med Rev 7:472–499. Libbey JE, Sweeten TL, McMahon WM, Fujinami RS. 2005. Autistic disorder and viral infections. J Neurovirol 11:1–10. Lipkin WI, Hornig M. 2003. Microbiology and immunology of autism spectrum disorders. Novartis Found Symp 251:129–143. Lord C, Pickles A, McLennan J, Rutter M, Bregman J, Folstein S, Fombonne E, Leboyer M, Minshew N. 1997. Diagnosing autism: analyses of data from the Autism Diagnostic Interview. J Autism Dev Disord 27:501–517. Nasralla M, Haier J, Nicolson GL. 1999. Multiple mycoplasmal infections detected in blood of patients with chronic fatigue syndrome and/or fibromyalgia. Eur J Clin Microbiol Infect Dis 18:859–865. Nasralla MY, Haier J, Nicolson NL, Nicolson GL. 2000. Examination of mycoplasmas in blood of 565 chronic illness patients by polymerase chain reaction. Int J Med Biol Environ 28:15–23. Nicolson GL, Berns P, Nasralla M, Haier J, Pomfret J. 2002. High frequency of systemic mycoplasmal infections in Gulf War veterans and civilians with amyotrophic lateral sclerosis (ALS). J Clin Neurosci 9: 525–529. Nicolson GL, Gan R, Haier J. 2003a. Multiple co-infections (Mycoplasma, Chlamydia, human herpesvirus-6) in blood of chronic fatigue syndrome patients: association with signs and symptoms. Acta Pathol Microbiol Immunol Scand 111:557–566. AQ2 Nicolson GL, Nasralla M, Gan R, Haier J, De Meirleir K. 2003b. Evidence for bacterial (Mycoplasma, Chlamydia) and viral (HHV-6) coin- fections in chronic fatigue syndrome patients. J Chronic Fatigue Syndr 11:7–20. Nicolson GL, Nasralla M, Nicolson NL, Haier J. 2003c. High prevalence of mycoplasmal infections in symptomatic (chronic fatigue syndrome) family members of mycoplasma-positive gulf war illness patients. J Chronic Fatigue Syndr 11:21–36. Nicolson GL, Gan R, Haier J. 2005a. Evidence for Brucella spp. and Mycoplasma spp. coinfections in blood of chronic fatigue syndrome patients. J Chronic Fatigue Syndr 12:5–17. Nicolson GL, Nicolson GL, Gan R, Haier J. 2005b. Chronic mycoplas- mal infections in Gulf War Veterans’ children and autism patients. Med Veritas 2:383–387. Nijs J, Nicolson GL, De Becker P, Coomans D, De Meirleir K. 2002. Prevalence of mycoplasmal infections in European CFS patients. Examination of four Mycoplasma species. FEMS Immunol Med Micro- biol 34:209–214. Pilowsky T, Yirmiya N, Shulman C, Dover R. 1998. The Autism Diagnostic Interview—Revised and the Childhood Autism Rating Scale: differences between diagnostic systems and comparison between genders. J Autism Dev Disord 28:143–151. Takahashi H, Arai S, Tanaka-Taya K, Okabe N. 2001. Autism and infection/immunization episodes in Japan. Jpn J Infect Dis 54:78–79. Thornton D. 1986. A survey of mycoplasma detection in vaccines. Vaccine 4:237–240. Van Bourgondien ME, Marcus LM, Schopler E. 1992. Comparison of DSM-III-R and childhood autism rating scale diagnoses of autism. J Autism Dev Disord 22:493–506. Veenstra-Vanderweele J, Cook E Jr, Lombroso PJ. 2003. Genetics of childhood disorders. XLVI. Autism, part 5, genetics of autism. J Am Acad Child Adolesc Psychiatry 42:116–118. Wilkerson DS, Volpe AG, Dean RS, Titus JB. 2002. Perinatal complica- tions as predictors of infantile autism. Int J Neurosci 112:1085–1098. Wing L, Leekam SR, Libby SJ, Gould SJ, et al. 2002. The diagnostic interview for social and communication disorders: background, inter- rater reliability and clinical use. J Child Psychol Psychiatry 43:307–325. Yamashita Y, Fujimoto C, Nakajima E, Isagai T, Matsuishi T. 2003. Pos- sible association between congenital cytomegalovirus infection and autistic disorder. J Autism Dev Disord 33:355–459. *Correspondence to: Prof. Garth L. Nicolson, Office of the President, The Institute for Molecular Medicine, 16371 Gothard Street H, Huntington Beach, California 92647. E-mail: firstname.lastname@example.org Received 24 January 2006; Revised 13 November 2006; Accepted 22 November 2006 Published online 00 Month 2007 in Wiley InterScience (www. interscience.wiley.com).